SubscribeLatest 5 articles from heartwire
- Guidance for cardiac patients considering high-altitude activities
Dec 28, 2009 09:00 EDT - Strongest evidence yet that Lp(a) causes heart disease
Dec 23, 2009 17:00 EDT - Myxo ring controversy makes front-page news in Wall Street Journal
Dec 23, 2009 16:00 EDT - Optimal duration of dual antiplatelet therapy after DES: 12 months, but more data coming
Dec 23, 2009 14:00 EDT - Pfizer licenses apoA-I Milano to the Medicines Company
Dec 23, 2009 13:15 EDT
Dabigatran: Crossing a remarkable threshold
Posted Oct 14, 2009
at 11:00 AM, EDT
by Eric Topol
The exciting results of the RE-LY trial appear to mark the beginning of a new era in anticoagulation for atrial fibrillation. Will dabigatran be the drug to replace warfarin, at last? How do you think these findings will improve patient care?
Disclosure: I have no relationship with the dabigatran's manufacturer (Boehringer Ingleheim) or any other forthcoming oral anticoagulant program in clinical development (DTI, Factor Xa, etc).
See:
RE-LY: Oral antithrombin dabigatran outshines warfarin in atrial fib
Best of Barcelona: PLATO and RE-LY
RE-LY: An obituary for Warfarin?
Previous postsBillets précédents
Twitter: A place in the medical world?
No commentsAucun commentaire |
Posted Dec 16, 2009
at 10:30 AM, EDT by Eric Publié le 12.16.2009 à 10h30 par Eric
at 10:30 AM, EDT by Eric Publié le 12.16.2009 à 10h30 par Eric
PACE: A trial that challenges dogma
No commentsAucun commentaire |
Posted Nov 24, 2009
at 01:50 PM, EDT by Eric Publié le 11.24.2009 à 13h50 par Eric
at 01:50 PM, EDT by Eric Publié le 11.24.2009 à 13h50 par Eric
Ezetimibe in ARBITER 6-HALTS: What lessons can we learn?
3 comments3 commentaires |
Posted Nov 16, 2009
at 05:00 PM, EDT by Eric Publié le 11.16.2009 à 17h00 par Eric
at 05:00 PM, EDT by Eric Publié le 11.16.2009 à 17h00 par Eric
Antiplatelet therapy: A step forward with individualized medicine
6 comments6 commentaires |
Posted Sep 22, 2009
at 10:30 AM, EDT by Eric Publié le 09.22.2009 à 10h30 par Eric
at 10:30 AM, EDT by Eric Publié le 09.22.2009 à 10h30 par Eric
Cash for clunkers, cash for lowering obesity rates
5 comments5 commentaires |
Posted Aug 24, 2009
at 01:50 PM, EDT by Eric Publié le 08.24.2009 à 13h50 par Eric
at 01:50 PM, EDT by Eric Publié le 08.24.2009 à 13h50 par Eric
Also from theheart.org
Blogs I read
Who's talking
|
Eric J Topol MD
Director, Scripps Translational Science Institute The Gary and Mary West Chair of Innovative Medicine Chief Academic Officer, Scripps Health La Jolla, CA |
CommentsCommentaires
Hi Eric,
You state you have no relation with Boeringer Ingleheim, producer of dabigatran.
Your policy (theheart.org):
"Disclosure
We disclose sources of funding and site contributors’ possible conflicts of interest."
You are Editor-in-Chief of all "theheart.org". As I understand it, this whole website is financed directly or indirectly mainly by money from the pharmaceutical industry.
Boeringer I. is one of the pharmaceutical companies paying for there special interest CME-event, disvcussions lead by Michael Weber or any other chairman pushing the most recent and most expensive alternative etc.
Can´t you, Eric J Topol, see any "possible conflict of interest" there? I can trust you anyway, I agree with you in most cases, but why say there is no potential for conflict of interests in your position as Editor-in-Chief?
If, a few years from now, dabigatran is an ordinary pill among others and the compliance of taking dabigatran regularly and strictly may be around 60-70% as it is for statins or antihypertensives. Because of monitoring warfarin compliance may be 95%. 95% compliance with warfarin or 60-70 % compliance of dabigatran, which will give the best stroke prevention do you think?
Anders Hernborg, M.D.
Halmstad, Sweden